• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 6, 2015

View Archived Issues

Amgen finds CAR T ride with Kite Pharma immunotherapy alliance

Amgen Inc. is bolstering its immuno-oncology franchise and making its first foray into the hot chimeric antigen receptor (CAR) T-cell therapy field through an early stage deal with Kite Pharma Inc. that, if successful, could prove lucrative for both firms. Read More

Chinese regulators issue first draft guidance on biologics stability

HONG KONG – Chinese pharmaceutical regulators will begin 2015 by taking aim at improving supervision of shelf-life studies and storage of biological products in order to enhance consumer safety. Read More

Oh boy: LADD gets $51.4M in Aduro series D financing; pancreatic phase II goes on

Tallying venture capital investments aplenty last year, Aduro Biotech Inc. chalked up more in a series D preferred stock financing of $51.4 million for its immuno-oncology pipeline, an amount that brings the total haul for the Berkeley, Calif.-based firm in 2014 to $106.4 million. Read More

Worm study has a skeptical view of life span extension's benefits

The search for ways to increase life span is based on the idea that such an increased life span will extend the good parts of life – meaning, by and large, the healthy parts. Read More

Extrapolation is big question for ODAC as it weighs first biosimilar

Seemingly confident in the level of similarity between Sandoz Inc.'s Zarxio and Amgen Inc.'s Neupogen, the FDA has one voting question for the Oncologic Drugs Advisory Committee (ODAC) that will weigh in Wednesday on what is likely to be the first U.S. biosimilar. Read More

VC flows big time with Moderna's record $450M financing

There's nothing like starting the new year on a high note with news of a record venture financing. Cambridge, Mass.-based Moderna Therapeutics Inc. said it closed a whopping $450 million financing that will fuel and expand its messenger RNA (mRNA) therapeutics platform across a number of therapeutic indications. Read More

Financings

Clementia Pharmaceuticals Inc., of Montreal, said it secured an additional $10 million from its current investors to support development of their lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP). Read More

Other news to note

Biomedx GmbH, of Heidelberg, Germany, said it entered a collaboration agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, to establish a research group focusing on the identification of therapeutic concepts for treating patients with chronic obstructive pulmonary disease (COPD). Read More

Stock movers

Read More

In the clinic

Cel-Sci Corp. shares (NYSE:CVM) rose 7 cents, or 11.3 percent, to 69 cents Monday, as the company reported that in 2014 it enrolled almost 200 patients with advanced primary, untreated head and neck cancer into its global pivotal phase III head and neck cancer trial for its investigational immunotherapy Multikine (leukocyte interleukin). Read More

Pharma: Other news to note

Bristol-Myers Squibb Co., of New York, the California Institute for Biomedical Research (Calibr) entered into a worldwide research collaboration to develop small-molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr's preclinical compounds resulting from the collaboration. Read More

Pharma: In the clinic

Fennec Pharmaceuticals Inc., of Research Triangle Park, N.C., said the second sodium thiosulfate (STS) phase III study, SIOPEL 6, has fully enrolled and is now closed for recruitment. Read More

Regulatory front

The National Institutes of Health (NIH) is seeking comments on its draft policy promoting the use of a single institutional review board (IRB) for all domestic sites in multisite studies funded by the institutes. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe